Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Page 1
Long-term benefits of a therapeutic make-up consultation for patients with various facial dermatoses.
Eur J Dermatol. 2023 Aug 1;33(4):419-425. doi: 10.1684/ejd.2023.4534.
Eur J Dermatol. 2023.
PMID: 37823493
BACKGROUND: Therapeutic make-up has previously been proven to be efficacious in improving the quality of life of patients with facial dermatoses, but its efficacy has only been assessed in the short term (less than one month). OBJECTIVES: This study aimed to determine whet …
BACKGROUND: Therapeutic make-up has previously been proven to be efficacious in improving the quality of life of patients with facial dermat …
Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial.
Gaborit B, Vanhove B, Vibet MA, Le Thuaut A, Lacombe K, Dubee V, Ader F, Ferre V, Vicaut E, Orain J, Le Bras M, Omnes A, Berly L, Jobert A, Morineau-Le Houssine P, Botturi K, Josien R, Flet L, Degauque N, Brouard S, Duvaux O, Poinas A, Raffi F; POLYCOR study group.
Gaborit B, et al. Among authors: vibet ma.
Trials. 2021 Mar 9;22(1):199. doi: 10.1186/s13063-021-05132-9.
Trials. 2021.
PMID: 33750432
Free PMC article.
Convalescent plasma to treat infected patients is therefore a relevant therapeutic option currently under assessment (CORIMUNO-PLASM NCT04324047). However, the difficulties of collecting plasma on the long term are not adapted to a broad use across all populations. New pol …
Convalescent plasma to treat infected patients is therefore a relevant therapeutic option currently under assessment (CORIMUNO-PLASM NCT0432 …
Item in Clipboard
Modeling the risk of fluoroquinolone resistance in non-severe community-onset pyelonephritis.
Leforestier A, Vibet MA, Gentet N, Javaudin F, Le Bastard Q, Montassier E, Batard E.
Leforestier A, et al. Among authors: vibet ma.
Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1123-1127. doi: 10.1007/s10096-020-03830-x. Epub 2020 Jan 30.
Eur J Clin Microbiol Infect Dis. 2020.
PMID: 31997098
A specific model was derived to identify district #2 patients with a low (10% or lower) probability of being infected by a fluoroquinolone resistant isolate. Independent risk factors were residency in long-term care facility (aOR, 3.3 (0.7-13.5)), and in the 6 previous mon …
A specific model was derived to identify district #2 patients with a low (10% or lower) probability of being infected by a fluoroquinolone r …
Item in Clipboard
Cite
Cite